PUBLISHER: The Business Research Company | PRODUCT CODE: 1947032
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947032
Pulsed field ablation is a minimally invasive cardiac procedure that delivers short bursts of high-voltage electrical pulses to selectively target and destroy abnormal heart tissue responsible for arrhythmias. This approach allows for precise ablation with minimal damage to surrounding tissues, offering a safer alternative to traditional ablation methods. It is increasingly used in the treatment of conditions such as atrial fibrillation.
The primary components of pulsed field ablation systems include catheters and generators. Catheters are flexible, tube-like medical instruments inserted into the body for the delivery or removal of fluids, as well as for performing diagnostic and therapeutic procedures. The key clinical indications for pulsed field ablation are atrial fibrillation and non-atrial fibrillation arrhythmias. Different ablation energy sources include pulsed field energy alone, pulsed field combined with radiofrequency energy, and pulsed field combined with cryoablation energy. The technology is used in various application areas such as ablation only or combined ablation and mapping. Major end users include hospitals, cardiac catheterization labs, ambulatory surgical centers, and other healthcare facilities.
Tariffs have influenced the pulsed field ablation market by affecting the cost of imported catheters, generators, and other specialized equipment. The increased import duties have raised production and procurement costs, particularly impacting segments like monopolar and bipolar generators and regions such as North America and Europe that rely on imported components. While the tariffs pose challenges in pricing and supply chain stability, they also encourage local manufacturing and innovation, enabling regional companies to develop cost-effective pulsed field ablation solutions.
The pulsed field ablation market research report is one of a series of new reports from The Business Research Company that provides pulsed field ablation market statistics, including pulsed field ablation industry global market size, regional shares, competitors with a pulsed field ablation market share, detailed pulsed field ablation market segments, market trends and opportunities, and any further data you may need to thrive in the pulsed field ablation industry. This pulsed field ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pulsed field ablation market size has grown exponentially in recent years. It will grow from $0.8 billion in 2025 to $0.99 billion in 2026 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to increasing prevalence of atrial fibrillation, adoption of catheter-based ablation techniques, advancements in cardiac mapping systems, rising awareness about cardiovascular diseases, technological innovations in pulsed field devices.
The pulsed field ablation market size is expected to see exponential growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 24.4%. The growth in the forecast period can be attributed to growing geriatric population, increasing healthcare infrastructure in emerging markets, integration of AI in ablation procedures, rising preference for minimally invasive treatments, development of combination ablation energy sources. Major trends in the forecast period include minimally invasive cardiac procedures, patient-specific ablation planning, enhanced safety and reduced tissue damage, integration of imaging and mapping technologies, rapid adoption in electrophysiology labs.
The increasing prevalence of atrial fibrillation is expected to drive the growth of the pulsed field ablation market. Atrial fibrillation is characterized by an irregular and often rapid heart rhythm that elevates the risk of stroke and other heart-related complications. This condition is becoming more common due to the aging population, as older individuals are significantly more likely to develop atrial fibrillation. Pulsed field ablation treats this condition by using controlled electrical pulses to precisely destroy abnormal heart tissue that causes irregular rhythms. It offers a quicker, safer, and more targeted alternative compared to traditional ablation techniques. For example, in December 2024, the Australian Institute of Health and Welfare reported that atrial fibrillation caused 2,600 deaths and contributed to 15,500 more in Australia in 2022. Death rates were 1.3 times higher among males, and over 62% of deaths occurred in people aged 85 and older, who faced up to 7.4 times greater risk than those aged 75-84. As a result, the rising incidence of atrial fibrillation is contributing to the expansion of the pulsed field ablation market.
Leading companies in the pulsed field ablation (PFA) market are focusing on innovative technologies such as selective tissue ablation to improve procedural safety and effectiveness. This approach targets only the diseased tissues while preserving surrounding healthy structures, which helps reduce recovery times and enhances long-term outcomes for patients with cardiac arrhythmias. For instance, in March 2025, Abbott, a US-based healthcare firm, received CE Mark approval for its Volt Pulsed Field Ablation System, designed to treat abnormal heart rhythms. The system integrates with Abbott's EnSite X electrophysiology platform, improving visualization and navigation during procedures. The Volt system marks a significant advancement in electrophysiology by increasing procedural efficiency, delivering sharper imaging, and ensuring more accurate ablation for atrial fibrillation treatment. This next-generation technology is set to enhance patient outcomes and optimize cardiac care delivery.
In January 2024, CardioFocus, a US-based medical device company, acquired the electrophysiology division of Galvanize Therapeutics to strengthen its pulsed field ablation offerings. The acquisition includes the CE-marked CENTAURI System and the developmental QuickShot catheter. This strategic move expands CardioFocus's footprint in the electrophysiology sector with both focal and single-shot PFA technologies. Galvanize Therapeutics is a US-based manufacturer known for developing the Aliya Pulsed Field Ablation (PFA) system.
Major companies operating in the pulsed field ablation market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, AtriCure Inc., CardioFocus Inc., Galvanize Therapeutics Inc., Kardium Inc., Acutus Medical Inc., AtriAN Medical Ltd., Field Medical Inc., Thermedical Inc., Adagio Medical Inc., Arga Medtech Inc., Mirai Medical, Pulse Biosciences Inc., AccuPulse Medical Inc., Farapulse Inc., Biosense Webster Inc., CathRx Ltd., EP Solutions SA
North America was the largest region in the pulsed field ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulsed field ablation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pulsed field ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The pulsed field ablation market consists of revenues earned by entities by providing services such as consultation and treatment planning services, remote monitoring and telehealth support, and device maintenance and calibration services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulsed field ablation market also includes sales of training simulators and educational tools and disposable consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pulsed Field Ablation Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pulsed field ablation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pulsed field ablation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulsed field ablation market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.